Drugs / GLPG3312
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03800472 | Jan 2019 → Mar 2020 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG3312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03800472 ↗ |
| Known as | compound 28 | “Following a high-throughput screening campaign, subsequent hit to lead optimization through synthesis, structure-activity relationship, kinome selectivity, and pharmacokinetic...” PMID 38147525 ↗ Dec 2023 |
| Action | Inhibit | “a potent and selective pan-SIK inhibitor (IC50: 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3)” PMID 38147525 ↗ Dec 2023 |
| Route | Oral | “Single and Multiple Ascending Oral Doses of GLPG3312” NCT03800472 ↗ |
| Target | SIK1 | “a potent and selective pan-SIK inhibitor (IC50: 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3)” PMID 38147525 ↗ Dec 2023 |
| Target | SIK2 | “a potent and selective pan-SIK inhibitor (IC50: 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3)” PMID 38147525 ↗ Dec 2023 |
| Target | SIK3 | “a potent and selective pan-SIK inhibitor (IC50: 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3)” PMID 38147525 ↗ Dec 2023 |